FDA approves first generic of Daraprim
- Details
- Category: FDA
The U.S. Food and Drug Administration has approved an application for the first generic of Daraprim (pyrimethamine) tablets for the treatment of toxoplasmosis (an infection caused by the parasite Toxoplasma gondii) when used with a sulfonamide (a group of medicines used to treat bacterial infections).
FDA takes action with Indian Government to protect consumers from illicit medical products
- Details
- Category: FDA
The U.S. Food and Drug Administration today announced that its first bilateral enforcement operation with the Government of India, stopped approximately 500 shipments of illicit, and potentially dangerous, unapproved prescription drugs and combination medical devices from reaching American consumers over the course of an operation that took place in January.
FDA approves first drug for treatment of peanut allergy for children
- Details
- Category: FDA
Today the U.S. Food and Drug Administration approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] to mitigate allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanuts. Treatment with Palforzia may be initiated in individuals ages 4 through 17 years with a confirmed diagnosis of peanut allergy and may be continued in individuals 4 years of age and older.
FDA continues strong support of innovation in development of gene therapy products
- Details
- Category: FDA
This is a pivotal time in the field of gene therapy as the FDA continues its efforts to support innovators developing new medical products for Americans and others around the world. To date, the FDA has approved four gene therapy products, which insert new genetic material into a patient's cells.
FDA approves first treatment option specifically for patients with epithelioid sarcoma
- Details
- Category: FDA
Today, the U.S. Food and Drug Administration granted accelerated approval to Tazverik (tazemetostat) for the treatment of adults and pediatric patients aged 16 years and older with metastatic (when cancer cells spread to other parts of the body) or locally advanced (when cancer has grown outside the organ it started in, but has not yet spread to distant parts of the body) epithelioid sarcoma not eligible for complete resection (surgically removing all of a tissue, structure, or organ).
FDA approves first treatment for thyroid eye disease
- Details
- Category: FDA
Today, the U.S. Food and Drug Administration (FDA) approved Tepezza (teprotumumab-trbw) for the treatment of adults with thyroid eye disease, a rare condition where the muscles and fatty tissues behind the eye become inflamed, causing the eyes to be pushed forward and bulge outwards (proptosis). Today's approval represents the first drug approved for the treatment of thyroid eye disease.
FDA approves the first targeted therapy to treat a rare mutation in patients with gastrointestinal stromal tumors
- Details
- Category: FDA
The U.S. Food and Drug Administration approved Ayvakit (avapritinib) for the treatment of adults with unresectable (unable to be removed with surgery) or metastatic (when cancer cells spread to other parts of the body) gastrointestinal stromal tumor (GIST) - a type of tumor that occurs in the gastrointestinal tract,
More Pharma News ...
- FDA approves new treatment for adults with migraine
- FDA approves first generics of Eliquis
- FDA approves new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies
- FDA approves new type of therapy to treat advanced urothelial cancer
- FDA grants accelerated approval to first targeted treatment for rare Duchenne muscular dystrophy mutation
- FDA launches app for health care professionals
- FDA approves first generics of Gilenya